Please assess the completion status of the following clinical trial:

Trial Title: Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects with a diagnosis of EPP (confirmed by elevated free protoporphyrin in peripheral erythrocytes) of sufficient severity that they have requested treatment to alleviate their symptoms.~* Aged 18 - 70 years (inclusive)~* Written informed consent prior to the performance of any study-specific procedures.~Exclusion Criteria:~* Any allergy to afamelanotide or the polymer contained in the implant or to lignocaine or other local anaesthetic to be used during the administration of study medication.~* EPP patients with significant hepatic involvement.~* Personal history of melanoma or dysplastic nevus syndrome.~* Current Bowen's disease, basal cell carcinoma, squamous cell carcinoma, or other malignant or premalignant skin lesions.~* Any other photodermatosis such as PLE, DLE or solar urticaria.~* Any evidence of clinically significant organ dysfunction or any clinically significant deviation from normal in the clinical or laboratory determinations.~* Acute history of drug or alcohol abuse (in the last 12 months).~* Patient assessed as not suitable for the study in the opinion of the Investigator (e.g. noncompliance history, allergic to local anaesthetics, faints when given injections or giving blood).~* Female who is pregnant (confirmed by positive serum β-HCG pregnancy test prior to baseline) or lactating.~* Females of child-bearing potential (pre-menopausal, not surgically sterile) not using adequate contraceptive measures (i.e. oral contraceptives, diaphragm plus spermicide, intrauterine device).~* Sexually active men with partners of child bearing potential not using barrier contraception during the trial and for a period of three months thereafter.~* Participation in a clinical trial of an investigational agent within 30 days prior to the screening visit.~* Prior and concomitant therapy with medications which may interfere with the objectives of the study, including drugs that cause photosensitivity or skin pigmentation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Afamelanotide (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).